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Aims: Stress urinary incontinence (SUI) is common in the adult females. Surgical
treatment options include synthetic mid-urethral sling (MUS), autologous sling,
bulking agents, andBurch colposuspension. The autologous pubovaginal sling (PVS)
has re-emerged in response to complications of synthetic MUSs and FDA
communications regarding the use of vaginal mesh. This resulted in patients’ fear
related to vaginal mesh and drop in number of patients seeking surgical treatment of
SUI. PVS has re-emerged as an option for treatment of primary SUI. The aim of this
review is to familiarize, disseminate information, and share tips for the practicing
female pelvic surgeons related to the practice of the autologous fascia sling.
Methods: We reviewed the literature related to the autologous sling. We used the
following data bases and search engines: GoPubMed (Transinsight), Cochrane
reviews (Wiley Interscience), google scholar (google), and Scopus (Elsevier).
Because it is the most commonly investigated and utilized, we focused on the
autologous rectus fascia sling. We also focused on the retropubic sling approach
because the literature on transobturator rectus fascia sling is sparse.
Results:Out of 307 articles related to the subject found, 22 articles were included and
the rest were excluded.
Conclusion:ARFS is a valid primary method of treatment for female SUI. Also, it is
used in particular indications such as patients with intrinsic sphincter deficiency
(ISD), prior pelvic irradiation, failed and/or complicated syntheticMUS, and violated
urethral lumen.
KEYWORDS
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1 | INTRODUCTION
The use of the autologous sling in treatment of female SUI
is known since the beginning of the last century. Synthetic
MUS emerged in the early 1990s and now is the most
commonly used procedure for female SUI.1–3 This procedure,
however, has increasingly been associated with sling-related
complications, malpractice litigations, and associated
Abbreviations: ARFS, autologous rectus fascia sling; CIC, clean intermittent catheterization; ISD, intrinsic sphincteric deficiency; MUI, mixed urinary
incontinence; MUS, mid-urethral sling; PVS, traditional autologous pubovaginal sling; SUI, stress urinary incontinence; UVF, urethrovaginal fistula.
David Ginsberg led the peer-review process as the Associate Editor responsible for the paper.
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patients’ concerns. This forced many synthetic sling
manufacturers to withdraw their products off the market.
Simultaneously many pelvic surgeons have reduced the
utilization of synthetic and increased the utilization of
autologous slings.4
The first use of a fascial suburethral sling was described
by Price in 1933 using fascia lata.5 Aldridge popularized the
use of the rectus fascia sling in 1942.6 In 1978, McGuire and
Lyton popularized the rectus fascia sling procedure for type
III-SUI (a severe form of SUI secondary to ISD).7 In 1986,
McGuire and his group reported on the use of free rectus
fascial strip in the treatment of SUI in patients with
myelodysplasia.8 This was further modified by Ghoneim in
1989.9 In 1991, Blaivas and Jacobs reported on the use of
ARFS in patients with complicated SUI.10
The purpose of this review article is to shed the light on
the autologous slings with special emphasis on procedure
technique, outcome, indications, and complications.
The term autologous sling refers to the use of patient-own-
tissue as a sling. In this article, we will discuss the ARFS
using the retropubic approach.
2 | METHODS
We reviewed the literature related to the autologous sling.We
used the keywords “autologous sling,” “rectus fascia sling,”
“autologous rectus fascia sling,” and “autologous female
sling.” We used the following data bases and search engines:
GoPubMed (Transinsight), Cochrane reviews (Wiley Inter-
science), google scholar (google), and Scopus (Elsevier). We
excluded meeting abstracts, case reports, case series, articles
related to autologous sling in male and autologous sling
materials other than rectus fascia.We also focused only on the
retropubic sling approach being the most popular and the
more investigated.
3 | RESULTS
We found 307 articles related to the subject, 22 articles were
included. We found that even with the wide availability of the
synthetic MUS, the autologous sling is still a valid primary
option for treatment of SUI. Although the number of studies is
limited, the outcome of autologous sling in specific type of
SUI patients who failed or have complicated synthetic MUS
seems favorable.
4 | DISCUSSION
4.1 | Mechanism of continence using the ARFS
The primarymechanism of PVS is creation of increased outlet
resistance. Clearly this is the case in obstructive PVS sling
where urinary retention is sought as in patients with
neurogenic bladder. But this action is not clear where both
self-voiding and continence are desired as in most cases. One
of the proposed mechanisms of action of ARFS is to restore
the normal urethrovesical junction support and mechanical
compression or kinking at the proximal urethra during stress.
This increases bladder outlet resistance during increased
intra-abdominal pressure and hence, prevents SUI.11 Video-
urodynamics in the standing position in patients who received
ARFS showed that during the resting position, the sling does
not have much compression role. During increased intra-
abdominal pressure, however, the rectus muscle contracts
pulling the sling anteriorly. This forward sling move leads to
rotation of the bladder base posteroinferiorly causing kinking
at the posterior urethra and increasing the bladder outlet
pressure which prevents SUI. This means applying overly
tension on the sling during sling positioning is unnecessary
and should be discouraged.11,12
4.2 | Indications
Although ARFS was reserved for complicated cases of SUI,
there is enough body of the literature to support the use of
ARFS as a primary treatment option for women with
uncomplicated SUI.13 Also, ARFS should be considered in
situations when the synthetic MUS is less preferred and/or
contraindicated. Those situations include violation of the
urethral mucosa either incidental during periurethral dissec-
tion or intentional during excision of urethral diverticulum,
closure of urethra-vaginal fistula, and/or excision of an
eroded synthetic sub-urethral sling.14,15 We also favor ARFS
for treatment of SUI in women with prior pelvic irradiation,
women on chronic steroid therapy, extensive tissue fibrosis
and scarring, and women with chronic pelvic pain and/or
dyspareunia.
4.3 | Surgical technique
The technique has been previously described by McGuire.7
While the patient in the modified dorsal lithotomy position
under general anesthesia, Foley catheter is inserted. A
Pfannenstiel suprapubic incision is made and the rectus
fascia is reached. The fascia is freed from the covering
subcutaneous fat. The sling outline is made by a marking
pen, methylene blue or the electrocautery (Figure 1). The
sling dimensions are of 8-10 cm long and 1.5-2 cm wide.
The marked fascial strip is then freed off circumferentially
from the rectus fascia. The ends of the sling are suspended
with 0 polypropylene (Prolene) or polydioxanone (PDS)
sutures, one on each side (Figure 2). A linear midline or
inverted U-vaginal incision is made at the level of the mid
urethra and up to the bladder neck level. The vaginal
epithelium is then dissected from the periurethral and
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pubocervical fascia till the inferior border of the pubic rami
are clearly palpated on each side. At this point, enough
space is created to reach the retropubic space. The bladder is
then evacuated. Proper needle passers are used and passed
from the suprapubic space down into the vaginal incision
(Figure 3). Different types of passers have been reported
including Stamey needle and McGuire ligature passer.11,16
We use the reusable MUS metal passers that have a gutter at
the tip, which allows for suture insertion. After the passers
are inserted on both sides, we remove the Foley catheter and
cystoscopy is performed to rule out bladder and/or urethral
perforation. The sling sutures are then inserted into the tip
of the passers on each side and the sutures are delivered in
an inside-out fashion delivering the sutures to the supra-
pubic region. The rectus fascial defect is closed with
continuous 00_PDS suture. Sling tension is adjusted in a
way that the assistant ties the Prolene sutures to each other
in the midline over two fingers. During the suture ligature
the surgeon observes for the sling tension and location
making sure the sling sits loose underneath the mid-urethra.
The sling is then secured to the periurethral fascia suing 3/0
absorbable sutures (Figure 4). It is only in situations when
we encounter severe ISD and when we use the ARFS for
creating a bladder outlet obstruction that we allow tight
sling positioning. In this later group of patients, we make
sure that the patient is comfortable with CIC or has a
suitable urinary diversion. We then close the vaginal and
abdominal incisions. A vaginal packing and the Foley
catheter are left in place. Patient is kept for overnight
observation. Both the vaginal packing and the Foley
catheter are removed in postoperative Day 1 and a trial
of void is performed same day. Patient then discharged
home.
4.4 | Effect of ARFS on urodynamic
parameters
In one multicenter study that included patients from the
SISTEr trial, 655 woman who had previously had either
Burch colposuspension or ARFS, had urodynamic studies
performed 2 years following their incontinence procedure. Of
the 655 patients included, 326 patients received ARFS as their
incontinence treatment. There was found significant reduc-
tion of the uroflowmetry in both the ARFS and the Burch
groups with more reduction in the uroflowmetry in the sling
group. The volume at first sensation was significantly
increased in both groups, the pressure flow studies showed
significant reduction of the Qmax with significant increase in
the Pdet at Q max in the sling group. There was an increased
bladder outlet index in both groups.17 Similar data were also
reported by others.18–21
4.5 | General outcome of ARFS
The overall success rate of the ARFS ranged between 31%
and 100%.11,22–24 In a recent meta-analysis of 15 855 patients,
synthetic MUSs and ARFS, were found to have similar
objective cure rates which were superior to Burch
colposuspension.25
In a systematic review and meta-analysis comparing
different procedures for SUI, the authors found that compared
to Burch colposuspension, ARFS results in lower rates of
wound infection, bladder or vaginal perforation, and bowel
injury. On the other hand, Burch colposuspension tends to
have less chance for mesh erosion, urinary retention that
indicates intervention, and overactive bladder symptoms.26
Athanasopoulos et al16 retrospectively reviewed the
charts of 264 female patients with SUI and who received
ARFS as the primary treatment. Themean follow-up timewas
27.8 (12-78) months. Two hundred patients (75.6%) had
complete resolution of their SUI, 24 patients (9.1%) had
marked improvement but still required one pad daily, and 40
FIGURE 1 Suprapubic incision and exposure of the rectus fascia
and the harvest of ARFS
FIGURE 2 Suspension of the sling ends with no absorbable
sutures; one on each side
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patients (15.2%) failed their procedure. Two hundred and
twenty-four patients (84.7%) were satisfied with the
procedure outcome. None of the preoperative factors of
age, prior anti-incontinence surgery, obesity, menopause, and
severity of incontinence, preoperative Valsalva leak point
pressure, presence of obstruction during urodynamics,
prolapse grade and/or the presence or absence of detrusor
overactivity was found to affect the outcome.
In the landmark SISTEr study by Albo et al, 655 patients
were randomized for either Burch colposuspension (329
patients) or ARFS (326 patients). The authors found a higher
success rate in the ARFS group in any incontinence and in the
stress specific incontinence.27 This success was found to be
maintained up to 5 years of follow-up (E-SISTEr).28
The outcome of theARFS compared to the syntheticMUS
was also. In a large cohort study that compared ARFS
(performed by a urologist) with the synthetic MUS
(performed by a gynecologist at the same institute), 242
women were investigated. Seventy-nine women obtained
ARFS and 163 women had MUS. At 3-year follow-up, the
mid urethral sling showed relatively higher success than the
ARFS in any incontinence, severe incontinence, and stress
specific incontinence. There was no difference in the
complications between the two groups; however, the ARFS
group tends to have more incidence of urine retention
requiring CIC, urethrolysis, or prolonged suprapubic tube
use.29
Wadie et al30 did a randomized clinical trial of 53 women
who had either autologous sling or tension-free vaginal tape.
The authors found no significant difference in the cure rates
between both groups after 6 months of follow-up.
4.6 | The outcome of ARFS after previous
synthetic sling excision
Recurrent SUI after complicated mesh sling release or
excision was reported in up to 39% of patients, with 14% of
patients need surgery for recurrent SUI after sling excision.31
Although another synthetic MUS can be used in those
patients, ARFS can be a reasonable alternative. This is with
the exception of associated urethral sling erosion; urethro-
vaginal fistula or sling related pelvic pain where only ARFS
should be used.32,33
The decision to insert an ARFS sling as one stage during
the mesh excision procedure or to postpone the ARFS to a
later stage has been a matter of debate. In our practice, we
advocate concomitant insertion of ARFS during complicated
mesh removal when there is an evidence of SUI before the
mesh excision procedure. We also favor concomitant
insertion of ARFS if extensive periurethral dissection is
FIGURE 3 Use of Stamey needle for sling delivery
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performed during mesh excision, or if the tissue quality is
poor. In case when tissue quality is questionable, we to use
Martius flap. It is imperative to have a detailed discussion
with the patient on the pros and cons of one- and two-stage
approaches.
In one stage approach, Shah et al reviewed their experience
in 21 patients who had removed synthetic MUS. Nineteen out
of those 21 patients received ARFS at the same time after
excision of complicated synthetic MUS. In this study, 14
patients had their mesh removed for urethral perforation and
seven patients had their mesh removed for bladder perforation.
Ten out of 14 (71%) urethral perforation and 7 out of 7 (100%)
bladder perforation patients were continent after their
secondary ARFS. Also in the latter group, there was no
further intervention needed. In the other four patients with
residual urinary incontinence, one patient had SUI and three
patients had urge incontinence after ARFS. Five out of the 14-
urethral perforation patients needed additional procedures after
the ARFS; one for treatment of urethrovaginal fistula, one for
severe SUI (which required a second ARFS), and the other
three patients developed urinary retention that subsequently
required ARFS sling lysis. Overall, four out of the 21 patients
had dyspareunia (Table 1).34
McCoy et al35 reported on patients who underwent
ARFS following previous synthetic MUS procedure. The
authors’ decision to concomitantly implant the ARFS
during mesh excision versus a two-stage procedure was
based on the surgeon's preference and patient's choice.
Furthermore, patients who had severe SUI or were
significantly bothered by it received concomitant ARFS.
Forty-six patients were included. Median follow-up was 9.3
months. Objective success was reported in 42 patients
(91%). There was 84.6% relative reduction in pad use.
Thirty-five (76%) patients perceived subjective success. Six
patients developed complications including three accidental
intraoperative urethrotomies or cystotomies. Ten patients
out of the 46 (22%), needed an average of 1.8 additional
procedures after the ARFS. Relative pad reduction was
reported in 93% of patients who had concomitant ARFS and
69% in patients who had staged ARFS. There was no
significant difference in the subjective success between the
two groups, with 93% success in the concomitant ARFS
group and 88% success in the staged ARFS group. It has to
be noted that patients who had staged ARFS in this study,
tend to have associated urethral erosion more likely than
those who had concomitant ARFS. This may contribute to
the discrepancy in the success between the two groups since
there is more tendency for aggressive dissection and hence
violation of the continence mechanism in the setting of
urethral erosion.
FIGURE 4 ARFS sling positioning
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In a prospective two-center study, Parker et al36 compared
the outcome of the ARFS in 229 patients who had the ARFS
as a primary treatment for their SUI with 59 patients who have
previously had MUS. Of the 59 patients who had prior MUS,
34 (57.4%) patients had failed sling with recurrent SUI, 20
(33.9%) patients had sling extrusion and five (8.5%) patients
developed sling related obstruction that required sling
excision or release. Median follow-up in the study was
14.7 months (1-124). There was found significant improve-
ment in the number of pads used and in the patients’ scoring of
the validated questionnaires in both groups. There was also
similar complication rate between the two groups. Urine
retention was more common in patients who had prior MUS
(8.5%) compared to the primary ARFS group (3.1%). Patients
who had prior MUS in the study tend to obtain more
additional incontinence procedures after ARFS (13.6%) than
those who had the ARFS as a primary treatment (3.5%).
The outcome of ARFS compared to the synthetic mid
urethral sling in the use of patients with recurrent or persistent
SUI after previous sling was also looked at. Aberger et al
retrospectively investigated the outcome of 224 patients who
failed prior MUS and subsequently received either synthetic
retropubicMUS (153 patients or 68.3%) or ARFS (71 patients
or 31.6%).37 The selection of the incontinence procedure was
based on patient's preference with the exception of patients
who had sling erosion and who were only offered ARFS. The
median follow-up in the study was 29 (minimum of 12)
months. There was no difference in the baseline abdominal
leak point pressure between both groups. The overall cure rate
was 61.4% in the synthetic sling group and 66.1% in the ARFS
group with no significant difference.
4.7 | Complications
The most common two important complications related to the
ARFS are de novo urgency and bladder outlet obstruction.
De novo urgency after AFRS is reported in 15-20% of
patients.16,38 In a study by Athanasopoulos et al,16 de novo
urgency was found in 49 patients (18.5%). Nineteen of those
patients (7.2%) had associated urgency incontinence.
De novo urgency after AFRS could be secondary to
increased bladder outlet pressure39–41 and disruption of the
bladder autonomic nerve supply during dissection.20
Voiding dysfunction and urinary retention after ARFS is
relatively higher than MUS with reported urine retention rate
between 5% and 20% and voiding difficulty rate between
1.5% and 7.8%.16,23,42 Preoperative voiding dysfunction and
urodynamic evidence of hypocontractile or acontractile
detrusor muscle are reported risk factors.43
The risk for long-termurinary retention is particularlyhigh in
patients who tend to strain to void. During straining, angulation
of the vesicourethral angle creates bladder outlet obstruction that
can worsen voiding dysfunction in those patients.39
Pelvic examination and post-void residual urine volume
assessmentmay help with the diagnosis. Pressure flow studies
are of low yield in detection of bladder outlet obstruction after
TABLE 1 ARFS after prior sling procedures
Authors N
Indication for
synthetic sling
removal
Follow-up
in months
(median)
Success
n/n (%)
Complications
n/n (%) Comments
Shah et
al34
21 Urethral/bladder
perforation
6-39 (16) 17/21 (89) 5/21 (24): UVF,
urine retention, and
recurrent SUI
7/7 (100%) success in
bladder perforation group
McCoy
et al35
46 Dyspareunia,
refractory
MUI or SUI, sling
erosion, extrusion,
and obstruction
(9.3) -Objective 42/46
(91)
-Subjective 35/46
(76)
6/46 (13)
Parker et
al36
59 Recurrent SUI, sling
extrusion, and sling
obstruction
1-124 (14.7) -Objective cure 32/
59 (54.2)
-Subjective cure 31/
59 (52.5)
-Combined
objective and
subjective: 27/59
(45.8)
-Any 21/59 (35.6)
Major: 2/59 (3.4)
Prospective two-center
cohort.
Aberger
et al37
71 Failure, extrusion,
erosion
12-93 (29) 44/71 (62) 12/71 (17) -Only 13/71 (18%) patients had
previous sling excised
-This cohort included patients with
failed both prior biological and
synthetic slings.
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ARFS. This was supported by others.44,45 If pressure flow
study is planned, we favor videourodynamics over regular
urodynamics in those situations to help detect the level of the
obstruction. We found no role for urodynamics in cases of
urinary retention after sling procedure. This observation is
supported by a study published by Aponte et al.46
Different from our early intervention approach to urinary
retention after synthetic MUS, we favor observation in
case of urinary retention after ARFS for up to 3 months
while patient is kept on regular CIC. The sling tension tends
to be spontaneously relieved over time probably secondary
to gradual loosening of the sling. If urinary retention
persists, sling incision with or without urethrolysis can be
performed.11,47–49
5 | CONCLUSIONS
ARFS is a reasonable primary treatment option for
uncomplicated female SUI. This procedure can also be
used after removal of synthetic MUS. We advocate
concomitant ARFS at the time of synthetic sling excision
in patients who have preoperative SUI, poor tissue quality,
and patients who choose to have prophylactic ARFS. ARFS
should be considered as a primary option of treatment for
female SUI in cases of urethral perforation, following repair
of urethrovaginal fistula, in irradiated urethra, and follow-
ing excision of urethral diverticulum. We also favor ARFS
over synthetic MUSs in female SUI associated with chronic
pelvic pain. ARFS procedure needs specific level of
surgical skills and surgeons who pursue this procedure
should obtain sufficient training before performing this
surgery.
ORCID
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